Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB, NASDAQ:MTFB), tells Proactive's Andrew Scott they've initiated a rolling submission of a new drug application to the US Food & Drug Administration for iclaprim.
The new drug application (NDA) for their flagship next-generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is expected to be completed during the second quarter of 2018.
Price: 0.63 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...
